Heparin-bonded circuits with a reduced anticoagulation protocol in primary CABG: A prospective, randomized study

Annals of Thoracic Surgery

Volumn 62, Issue 2, 1996, Pages 410-418

  Aldea, Gabriel S ^a,b   Doursounian, Mheir ^a,b   O'Gara, Paul ^a,b   Treanor, Patrick ^a,b   Shapira, Oz M ^a,b   Lazar, Harold L ^a,b   Shemin, Richard J ^a,b  

^a BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; GLYCERYL TRINITRATE; HEPARIN;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BLEEDING; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DOSE RESPONSE; FEMALE; GRAFT OCCLUSION; HEART MUSCLE REVASCULARIZATION; HEPARINIZATION; HUMAN; INTENSIVE CARE; MAJOR CLINICAL STUDY; MALE; PARTIAL THROMBOPLASTIN TIME; PEROPERATIVE COMPLICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 0030217969     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/0003-4975(96)00324-4     Document Type: Article

References (34)

1. 1. Scott WJ, Rode R, Castelmain B, et al. Efficacy, complication and cost of a comprehensive blood conservation program for cardiac operations. J Thorac Cardiovasc Surg 1992;103: 1001-7.
2. 2. Pfaender LM. Hemodynamics in extracorporeal aortic cannula: review of factors affecting choice of appropriate size. J Extra-Corporeal Tech 1981;13:224-32.
3. 3. Fremes SE, Wong BI, Lee E, et al. Metaanalysis of prophylactic drug treatment in the prevention of postoperative bleeding. Ann Thorac Surg 1994;58:1580-8.
4. 4. Cosgrove DM III, Heric B, Lytle BW, et al. Aprotinin therapy for re-operative myocardial revascularization: a placebo controlled study. Ann Thorac Surg 1992;54:1031-8.
5. 5. Yau TM, Carson S, Weisel RD, et al. The effect of warm heart surgery on post-operative bleeding. J Thorac Cardiovasc Surg 1992;103:1155-63.
6. 6. Schonberger JPAM, Everts PAM, Hoffmann JJ. Systemic blood activation with open and closed venous reservoirs. Ann Thorac Surg 1995;59:1549-55.
7. 7. Jobes DR, Aitkens GL, Shaffer GW. Increased accuracy and precision of heparin and protamine dosing reduces blood and transfusions in patients undergoing primary cardiac operation. J Thorac Cardiovasc Surg 1995;110:46-54.
8. 8. Khuri SF, Valeri R, Losclazo J, et al. Heparin causes platelet dysfunction and indices of fibrinolysis before cardiopulmonary bypass. Ann Thorac Surg 1995;60:1008-14.
9. 9. Young JA, Kisher CT, Doty DB. Adequate anticoagulation during cardiopulmonary bypass determined by activated clotting time and appearance of fibrin monomer. Ann Thorac Surg 1978;26:231-40.
10. 10. Cardoso PFG, Yamazaki F, Keshavjee S, et al. A reevaluation of heparin requirements for cardiopulmonary bypass. J Thorac Cardiovasc Surg 1991;101:153-60.
11. 11. Von Segesser LK, Weiss BK, Pasic M, et al. Risk and benefits of low systemic heparinization during open heart operations. Ann Thorac Surg 1994;58:391-8.
12. 12. Ovrum E, Holen EA, Tangen G, et al. Completely heparinized cardiopulmonary bypass and reduced systemic heparin: clinical and hemostatic effects. Ann Thorac Surg 1995; 60:365-71.
13. 13. Gu YJ, van Oeveren W, van der Kamp KWHJ, et al. Heparin-coating of extracorporeal circuits reduce thrombin formation in patients undergoing cardiopulmonary bypass. Perfusion 1991;6:221-5.
14. 14. Borowiec JW, Bylock A, van der Linden J, et al. Heparin reduces blood cell adhesion to arterial filters during coronary bypass: a clinical study. Ann Thorac Surg 1993;55:1540-5.
15. 15. Arnander C, Olsson P. Influence of blood flow and the effect of protamine on thromboresistant properties of covalently bonded heparin surface. Biomed Mat Res 1988;22:859-68.
16. 16. Redmond JM, Gillinov AV, Stuart RS, et al. Heparin-coated bypass reduce pulmonary injury. Ann Thorac Surg 1993;56: 474-8.
17. 17. Westaby S. Aspects of biocompatibility in cardiopulmonary bypass. CRC Crit Rev Biocompatibility 1987;3:193-234.
18. 18. Edmunds LH Jr. Breaking the blood-biomaterial barrier. ASAIO J 1995;41:824-30.
19. 19. Hashimoto K, Miyamoto H, Suzuki K, et al. Evidence of organ damage after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1992;104:666-73.
20. 20. Kirklin JK. The post-perfusion syndrome: inflammation and the damaging effects of cardiopulmonary bypass. In: Tinker J, ed. Cardiopulmonary bypass, current concepts and controversies. Philadelphia: WB Saunders, 1989:131-46.
21. 21. Bukhari EA, Krukenkamp IB, Burns PG, et al. Does aprotinin increase the myocardial damage in the setting of ischemia and preconditioning? Ann Thorac Surg 1995;60:307-10.
22. 22. Feindt PR, Walcher S, Volkmer I, et al. Effect of high dose aprotinin in aortocoronary bypass grafting. Ann Thorac Surg 1995;60:1076-80.
23. 23. Feindt P, Sefert U, Volkmer I, et al. Is there a phase of "hypercoagulability" when aprotinin is used in cardiac surgery? Eur J Cardiothorac Surg 1994;8:308-13.
24. 24. Chenoweth DE, Copper SW, Hugli TE, et al. Complement activation during cardiopulmonary bypass: evidence for generation of C3a and C5a anaphylatoxins. N Engl J Med 1981;304:497-503.
25. 25. Hsu LC, Loar ME, Tong SD. Thromboresistant properties of surface modified arterial filters. J Trans Soc Biomater 1991; 14:112.
26. 26. Gott VL, Whiffen JD, Datton RC. Heparin bonding on colloidal graphite surfaces. Science 1963;142:1297-8.
27. 27. Edmunds LH Jr. Surface-bound heparin - panacea or peril? Ann Thorac Surg 1994;58:285-6.
28. 28. Øvrum E, Mollnes TE, Fosse E, et al. High and low heparin dose with heparin-coated cardiopulmonary bypass circuits: activation of complement and granulocytes. Ann Thorac Surg 1995;60:1755-61.
29. 29. Gu YJ, van Oeveren W, Akkerman C, et al. Heparin-coated circuits reduce the inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 1993;55:917-22.
30. 30. Hsu LC. Heparin coating of bypass circuits: principles of heparin coating techniques. Perfusion 1991;6:209-19.
31. 31. Wendel HP, Heller W, Hoffmeister HE. Pathway of platelet protection in heparin-coated devices and its significance for cardiac surgery. Trans Soc Biomater 1995;21:281.
32. 32. Young BR, Lambrecht LK, Albrecht RM, et al. Platelet-protein interaction at blood-polymer interfaces in the canine test model. ASAIO Trans 1983;29:442-6.
33. 33. Tong SD, Rolfs MR, Hsu LC. Evaluation of Duraflo II heparin immobilized cardiopulmonary bypass circuits. ASAIO J 1990;36:654-6.
34. 34. Øvrum E, Brosstad F, Holen EA, et al. Effects of coagulation and fibrinolysis with reduced versus full anticoagulation and heparin-coated cardiopulmonary bypass. Circulation 1995; 92:2579-84.